TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05040126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Participants will have a screening period of up to 14 days and will be randomized to one of the study arms in the ratio of 1:1:1, using an interactive web response system.~Each participant will receive 26 weeks of treatment. If the participant's 16th-week sample remains culture positive, treatment will be extended up to 39 weeks.~Participants will be followed for 48 weeks after the end of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bedaquiline
Description: Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bedaquiline
Description: Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 24 weeks in all three arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pretomanid
Description: Pretomanid is administered as one tablet once a day for 26 weeks in all three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is administered as one tablet once a day for 26 weeks in all three arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pretomanid
Description: Pretomanid is administered as one tablet once a day for 26 weeks in all three arms
Study: NCT04622644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: clinical investigation microwave device class IIa not marked CE for stroke detection
Description: Patients with hyperacute stroke are referred to the emergency room with a 'stroke code'. Clinical collected data includes NIHSS and mRS. Patients will undergo to NCCT in order to exclude the haemorragic nature of vascular disease. In the same diagnostic session the patient undergo to CTA with tri-phase protocol to assess LVO. Before starting the CTA acquisition with iodinate contrast injection the StrokeWave will be placed on the head of the patients in the CT room passing toward the gantry of the CT avoiding any loose of time. The scanning with the StrokeWave will be performed in about 5 minutes and the system will be removed allowing the CTA acquisition.
Study: NCT05054257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous CAR19 T lymphocytes
Description: First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL
Study: NCT05688397

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental 1
Description: L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental 2
Description: L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over
Study: NCT05246696

Intervention type: OTHER
Intervention: BodyBabe questionnaire
Description: assessment of young mothers' perceptions using self-questionnaires
Study: NCT03543852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SurvivorLink
Description: SurvivorLink (www.cancersurvivorlink.org) was developed in 2010 as a HIPAA compliant web-based communication tool to enable survivors to learn about survivorship care, store their SHP and other important health documents, and share their SHP and other health documents with their various healthcare providers. Once the registrant creates their health record, they can upload and store their important health documents and electronically share their health record with their providers. Other key features include a provider directory for patients to find physicians knowledgeable of survivor care, additional patient/parent material available in English/Spanish, and additional continuing medical education (CME) modules for providers to learn about survivor care.
Study: NCT06103279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 1 tablet once daily of (EMPAGLIMAX® 10 mg) continuously starting from 1 week before starting doxorubicin till the end of last Dox-based chemotherapy dose according to the given chemotherapy protocol
Study: NCT05410821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
Description: radionuclide therapy using 177Lu-DOTA-EB-FAPI 60 mCi (2.22 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-FAPI 2 radionuclide therapy
Description: radionuclide therapy using 177Lu-DOTA-EB-FAPI 90 mCi (3.33 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-EB-FAPI 3 radionuclide therapy
Description: radionuclide therapy using 177Lu-DOTA-EB-FAPI 135 mCi (4.99 GBq) will be performed 6-weekly. A maximum of 2 cycles will be administered.
Study: NCT05827003

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised exercise program with a physiotherapist for 6 weeks, two days a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Supervised exercise program with a physiotherapist for 6 weeks, two days a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise&Topical Agent
Description: Diclofenac gel application to the knee joint twice a day, four days a week, in addition to a supervised exercise program under the supervision of a physiotherapist for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Agent
Description: Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Topical Agent
Description: Application of diclofenac gel to the knee joint twice a day, four days a week, for 6 weeks
Study: NCT05405270

Intervention type: DRUG
Intervention: Imiquimod
Description: Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.

Intervention type: DRUG
Intervention: Imiquimod
Description: Imiquimod 5% will be administered in the evening by either a vaginal applicator or administered on a vaginal tampon for three times a week during 16 weeks. Treatment efficacy will be evaluated after 20 weeks, by colposcopy with diagnostic biopsies, and at 6 months after completion of imiquimod therapy with cytology and if indicated histology.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3x vaginal swab for microbiome analysis
Description: A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.

Intervention type: DIAGNOSTIC_TEST
Intervention: 3x vaginal swab for microbiome analysis
Description: A vaginal swab will be taken from all patients at inclusion (before start of imiquimod), at colposcopy 20 weeks after start of imiquimod and at 6 months after completion of imiquimod treatment during follow-up appointment.

Intervention type: OTHER
Intervention: Expectative management
Description: Expectative management of CIN 2 when preferred by the patient. Follow-up 6 months after baseline colposcopy with cytology and if indicated histology.
Study: NCT05893316

Intervention type: DIAGNOSTIC_TEST
Intervention: urine sample collection
Description: The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.

Intervention type: DIAGNOSTIC_TEST
Intervention: urine sample collection
Description: The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN.
Study: NCT05357859

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solubilized vitamin D3
Description: solubilized vitamin D3
Study: NCT05452681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive Y-AMBIENT
Study: NCT05405270

Intervention type: DIAGNOSTIC_TEST
Intervention: 2x vaginal swab for microbiome analysis
Description: A vaginal swab will be taken from all patients at inclusion and at 6 months after inclusion during follow-up appointment.
Study: NCT05452681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT04744103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCA
Description: Patients will receive a TCA peel as a treatment for their actinic cheilitis.
Study: NCT05010473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and non-speech sound stimulation
Description: Listening to repetitive and extended sound presentation induces specific neural and physiological activity that we will measure via electroencephalography and pupillometry
Study: NCT05452681

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: Receive cookbook and socialization calls
Study: NCT06425783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warmed Blood Transfusion
Description: The erythrocyte suspension will be heated between 34-36 C⁰, which is the determined physiological temperature.~Before giving it to the baby, 2 ml of blood will be taken through a triple tap and its hematocrit and K value (blood gas) will be checked. It will be given to the baby after the temperature is checked with a body fluid thermometer and determined to be within the appropriate range and if hemolysis is not observed.~At the end of the standard transfusion period of 3 hours, all babies will be routinely checked for blood gases, HTC and K.
Study: NCT04943861

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weCare/Secure
Description: The weCare intervention is based on the social cognitive and empowerment theories and social support and is currently designed to reduce missed HIV care appointments and increase viral suppression among PWH who are newly diagnosed or out of care through the use of peer navigation and mHealth

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: There is no peer navigation within usual care.
Study: NCT05357859

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: medium chain triglyceride
Description: MCT with same amount
Study: NCT04890821

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CI Percutaneous Ring Annuloplasty System
Description: Percutaneous transcatheter implant and adjustment of the CI ring annuloplasty system.
Study: NCT04861961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DS vs. SADI-S vs. OAGBP
Description: Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DS vs. SADI-S vs. OAGBP
Description: Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DS vs. SADI-S vs. OAGBP
Description: Randomizacion of candidates for either conventional DS, SADI-S or OAGBP.
Study: NCT06227702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management according to Venous Excess Ultrasound (VExUS) Score
Description: Management of furosemide intravenous infusion according to VeXus results
Study: NCT06330662

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only
Description: The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Testing the effectiveness of hyaluronic acid in experimental group using a coronally advanced flap compared to a control group using a coronally advanced flap only
Description: The potential benefit of adding hyaluronic acid (HA) to the coronally advanced flap (CAF) operative technique to cover multiple adjacent recessions has not been sufficiently investigated. Improving aesthetics is one of the primary goals of root recession coverage periodontal surgery, and little is known about the same in multiple adjacent gingival recession coverage therapy. In patients with a sufficient amount (≥2 mm) of keratinized tissue, the coronally advanced flap (CAF) has been shown to be very effective in the treatment of multiple recessions, especially in terms of aesthetic results. The researchers concluded from a database search (Epistemonikos, Cochrane, Medline) that there is no evidence to support the use of HA + CAF to achieve greater root coverage in the treatment of multiple gingival recessions.
Study: NCT05261672

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam/ bupivaciane
Description: 20 ml bupivacaine 0.25% will be injected + 2 mg midazolam in 1 ml saline on each side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 20 ml bupivacaine 0.25% will be injected + 1 ml saline on each side
Study: NCT04713566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral rinces
Description: natural and commercial oral rinses were compared for efficacy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral rinces
Description: natural and commercial oral rinses were compared for efficacy
Study: NCT05744115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-PSMA-11
Description: Ga-68-PSMA-11 is produced via a lyophilized Sterile Cold kit. Ga-68 is eluted from a Ge-68/Ga-68 generator into a vial containing the premixed peptide and buffer. PSMA-11 radiolabeled with Ga-68 is administered to patients following verification of standard quality controls including activity measurement, pH, radiochemical purity, and visual inspection
Study: NCT05465031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan
Description: Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sacubitril-valsartan
Description: Sacubitril/valsartan (Entresto®) administered in the target dose of 200 mg b.i.d. (97/103 mg of sacubitril and valsartan respectively) for the period of 24 months. In case of target dose intolerance, the physician-in-charge will be able to reduce the dose to 100 mg b.i.d. (49/51mg of sacubitril and valsartan respectively). Physicians will be strongly encouraged to evaluate the possibility of drug dose uptitration to the target dose of 200 mg b.i.d.
Study: NCT06116058

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group A: integrated neuromuscular inhibition technique
Description: will receive integrated neuromuscular inhibition in addition to conventional treatment,INIT which included IC, SCS, and MET for the low back region for the quadratus lumborum( QL) and erector spinae (ES) muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Group B :Instrument assissted soft tissue mobilization
Description: IASTM performed on lumbar posterior muscle erector spinae (iliocostalis, longissimus), and quadratus lumborum(QL) The IASTM treatment was applied for approximately 20-seconds in a direction parallel to the muscle fibers being treated with the instrument at a 45° angle. Followed immediately by treating the muscles in a direction perpendicular to the muscle fibers with the instrument at a 45° angle for an additional 20-seconds, resulting in a total treatment time of approximately 40 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group C conventional physical therapy
Description: . The control group will applied general exercise. General exercise were applied with stretching exercises and stationary bicycling for 10-15 minutes14, 15) . Three sets of fifteen repetitions will performed, with rest times of 1 minute between sets during 4 weeks.
Study: NCT05663918

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self- determined Intensity Interval Training
Description: Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self- determined Intensity Interval Training
Description: Individuals will participate in 3 sessions of Self Determined Intensity Interval training, using a cycle ergometer, for 4 weeks.Ratings of Perceived exertion (RPE) will be measured using a Borg's 6-20 scale. (44). Users will be asked to exercise on a stationary bike at an intensity whereby there RPE is challenging. The cycling protocol includes five, 1-minute cycling intervals, interspersed with 1.5 minutes of recovery (cycling at a slow pace to bring the individuals heart rate down). Participants will also perform a 3-minute warm-up and a 2-minute cool-down for a total exercise duration of 17.5 minutes
Study: NCT05032326

Intervention type: DRUG
Group type: OTHER
Intervention: Follow-up study of the treated cohort
Description: follow-up study of the patients in the treated cohort: that have been included in the otbb3 study
Study: NCT05766605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Study: NCT05032326

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up study of the untreated cohort
Description: follow-up study of the patients in the untreated cohort: that have NOT been included in the otbb3 study
Study: NCT06083402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HyaCera™
Description: 1 Ritual HyaCera capsule once daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule once daily
Study: NCT05650177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended Mindfulness-Based Intervention (bMBI)
Description: The blended Mindfulness-Based Intervention (bMBI) is a 24-week online course 'blended' with therapist support via video link. The entire course is completed online and requires no in person contact. The bMBI follows the general structure of Mindfulness-Based Cognitive Therapy (MBCT) with an added emphasis on the cultivation of self-compassion. The bMBI comprises of 9-themed sessions spread out over the 24-weeks. Each session involves: video instructions, written information, psycho-educational exercises, and guided meditation practices. Participants meditate for 30-minutes each day. Additional homework involves short daily activities designed to incorporate mindfulness into daily life and keeping a journal about experiences within and around the practices and exercises. The therapist sessions are every two weeks and last for 45-minutes and help participants overcome any problems they experience.